Interferon alpha-2a biosimilar (Biosidus)

干扰素α-2a生物类似药 (Biosidus)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon alpha-2a biosimilar (Biosidus)
Drug Alias Namenterferon alfa 2a干扰素α-2a生物仿制药 (Biosidus)Biosidus interferon alpha 2aInferonInmutag +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis CSarcoma, KaposiHepatitis B
Global Approved IndicationsHepatitis CSarcoma, KaposiHepatitis B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2011/01/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiosidus
China Registration ClassN/A

Develop Information

Active CompaniesBiosidus
Inactive CompaniesN/A
Active IndicationsHepatitis CSarcoma, KaposiHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeL03AB04
Related LinksN/A